SD 170

structure given in first source

Also Known As:

3',5'-dichloro-2,4'-dihydroxybenzanilide; N-salicylo-(2,6-dichloro-4-aminophenol); SD-170; Benzamide, N-(3,5-dichloro-4-hydroxyphenyl)-2-hydroxy-

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

1.	Cuesta Rodríguez, T: 1 article (10/2004)
2.	Fernández Rubio, E: 1 article (10/2004)

1.	Pain (Aches) 07/01/2006 - "A validated visual analogue scale was used to assess pain in the recovery room, 3 h after the operation and on post-operative days 1, 2 and 3. A cystogram was performed on post-operative day 5. Operating time was significantly shorter in the RRP group versus the LRP group (mean+/-SD, 170+/-34. "
2.	Neoplasms (Cancer) 01/15/1984 - "3',5'-Dichloro-2,4'-dihydroxybenzanilide, an inhibitor of histidine decarboxylase, inhibited skin tumor promotion induced by 12-O-tetradecanoylphorbol-13-acetate in mice."
3.	Esophagitis 11/01/1987 - "During fungal esophagitis CRP was elevated, with peak values ranging from 73 to 380 mg/l (mean +/- SD: 170 +/- 104 mg/l). "
4.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/01/1981 - "Experimental allergic encephalomyelitis: suppression with SD-170, a new synthetic drug."
5.	Cataract (Cataracts) 10/01/2004 - "Retrospective study of the preoperative conjunctival flora of 784 patients operated on for cataracts in both eyes, in two operations separated by 213 days (SD 170), from November 1993 to December 1997. "